HeterogeneousHER2Gene Amplification

Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial

(2011) John M.S. Bartlett et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial

(2011) Cornelis JH van de Velde et al.   LANCET

Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)

(2010) John MS Bartlett et al.   LANCET ONCOLOGY

Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations

(2009) Guido Sauter et al.   JOURNAL OF CLINICAL ONCOLOGY

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

(2009) Paul Ellis et al.   LANCET

Determination ofHER2Amplification by In Situ Hybridization

(2008) John M.S. Bartlett et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

External Quality Assurance of HER2 FISH and ISH Testing

(2008) John M.S. Bartlett et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer

(2008) M. F. Press et al.   CLINICAL CANCER RESEARCH

HER2 testing in the UK: further update to recommendations

(2008) R A Walker et al.   JOURNAL OF CLINICAL PATHOLOGY